Oculus Wins China Approval for Animal Wound Product

Includes: BAYRY, OCLS
by: ChinaBio Today

Oculus Innovative Sciences (NSDQ: OCLS) of California reported that its partners have received China regulatory approval to market its wound healing solution as an animal product. Based on the company’s Microcyn technology, Vetericyn products speed the healing of wounds while fighting infection. Bayer (OTCPK:BAYRY) Animal Health secured the approvals in China and Taiwan.

Oculus is currently negotiating distribution agreements with Bayer, involving both pricing and minimum purchases, for the two countries.

Microcyn is an oxygenated water product that disinfects, giving the externally applied product the ability to kill spores, fungi and viruses. In animals, it is applied as a spray or a gel. The product provides a moist environment to promote healing while decreasing harmful microorganisms. Because it discourages infections, the product lowers the need for antibiotics.

The human products, marketed under the Microcyn label, are distributed in China by China Bao Tai. They received SFDA approval in 2008.

Disclosure: none.